Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves new monofocal IOL ➤ Topline Phase 3 results for fixed-dose combination presbyopia drop ➤ Gene therapy trial produces positive Phase 1/2 data for Leber congenital amaurosis ➤ New data shows investigational compound protects endothelium for cataract patients undergoing Fuchs treatment ➤ ASCRS news and events
➤ First in-human, non-invasive femtosecond laser trabeculotomy data ➤ Special Protocol Assessment received for Phase 2b/3 trial for dry AMD treatment ➤ FDA gives clearance to IND for geographic atrophy treatment ➤ Positive preliminary data in trial for retinitis pigmentosa and Leber congenital amaurosis therapy ➤ Wet AMD treatment proceeds to Phase 2 trial ➤ ASCRS news and events
➤ Fast-Track Designation granted for persistent epithelial defect treatment ➤ Study: automated capsulotomy device and white cataracts ➤ Dose escalation complete for Phase 1/2 study evaluating an RP treatment ➤ Companies enter agreement for sustained-release glaucoma treatment ➤ ASCRS news and events
➤ FDA approves twice-daily use of presbyopia drop ➤ Study: drug approved for high blood pressure shows promise for blinding childhood disease ➤ Breakthrough device designation granted to investigational dry AMD therapy ➤ Positive topline results for Phase 2 study of retinitis pigmentosa treatment ➤ FDA approves pediatric enrollment in trial for retinitis pigmentosa and Leber congenital amaurosis ➤ ASCRS news and events
➤ Patient enrollment complete for sustained release AMD therapy trial ➤ First patient dosed with corneal endothelial cell substitute ➤ First patient dosed in RNAi therapy for wet and dry AMD ➤ Study: early signs of corneal graft rejection reversed with steroid nanoparticle ➤ Company announces anti-VEGF market tracker ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Allogenic cell therapy receives regulatory approval for bullous keratopathy indication ➤ 24-month data on AMD photobiomodulation therapy ➤ Patient enrollment complete for Phase 3 trial evaluating topical presbyopia treatment ➤ Pre-IND meeting for treatment of corneal endothelial disease ➤ IND submitted for geographic atrophy treatment ➤ Second Phase 3 trial for dry eye disease therapy ➤ ASCRS news and events
➤ Positive preclinical results for non-viral gene therapy platform ➤ Real-world data confirms efficacy of investigational LHON therapy ➤ Largest genome wide study of photoreceptor cells to date ➤ CDC continues to investigate infectious outbreak associated with artificial tear use ➤ Updates from AAV-based gene therapy program for retinal conditions ➤ ASCRS news and events
➤ Results from investigational non-incisional glaucoma treatment ➤ Study: preservative-free latanoprost efficacy similar to preserved alternative ➤ FDA accepts priority review NDA for vitreoretinal lymphoma treatment ➤ Companies partner to develop dry eye drop ➤ Company announces lead asset in its agonist antibody pipeline ➤ ASCRS news and events
➤ NDA submitted for sustained-release travoprost implant ➤ BLA for wet AMD, DME, DR treatment accepted with priority review ➤ Topline results from 12-month safety clinical trial for investigational dry eye drug ➤ Companies collaborate for research on sustained release for investigational GA drug ➤ ASCRS news and events
➤ First FDA-approved treatment for geographic atrophy ➤ FDA accepts NDA for presbyopia drop ➤ NDA for geographic atrophy drug accepted with priority review ➤ Study: 5-year visual field data with MIGS device ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.